ProCE Banner Activity

Considerations in Selecting Therapy for Previously Treated Chronic Lymphocytic Leukemia

Slideset Download

Download this slideset from a live symposium at ASH 2021 for expert perspectives on best practices in treating patients with relapsed/refractory CLL.

Released: December 09, 2021

Expiration: December 08, 2022

Share

Faculty

Brian T. Hill

Brian T. Hill, MD, PhD

Director, Lymphoid Malignancies Program
Staff Physician, Department of Hematology and Medical Oncology
Taussig Cancer Institute
Cleveland Clinic
Cleveland, Ohio

Provided by

Provided by the National Comprehensive Cancer Network in collaboration with Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

BeiGene, Ltd.

Genentech, a member of the Roche Group

Janssen Biotech Pharmacyclics Abbvie

Faculty Disclosure

Primary Author

Brian T. Hill, MD, PhD

Director, Lymphoid Malignancies Program
Staff Physician, Department of Hematology and Medical Oncology
Taussig Cancer Institute
Cleveland Clinic
Cleveland, Ohio

Brian T. Hill, MD, PhD: consultant/advisor/speaker: AstraZeneca, BeiGene, Bristol Myers Squibb, Genentech, Genmab/AbbVie, Pharmacyclics.

Additional Information

Program Medium

This program has been made available online.